Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3923MR)

This product GTTS-WQ3923MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3923MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3517MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ9394MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ12219MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ3544MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ7313MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ3007MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ4579MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ10000MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW